Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study

References 

1. Albano C, Smitz J, Tournaye H, et al. Luteal phase and clinical outcome after human menopausal onadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection cycles. Human Reproduction. 1999;14:1426–1430
2. Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology and Metabolism. 2003;88:4186–4192
3. Chillik CF, Itskovitz J, Hahn DW, et al. Characterizing pituitary response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: tonic follicle-stimulating hormone/luteinizing hormone secretion versus acute GnRH challenge tests before, during, and after treatment. Fertility and Sterility. 1987;48:480–485
   • MEDLINE
4. Csapo AI, Pulkkinen MO, Ruttner B, et al. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. American Journal of Obstetrics and Gynecology. 1972;112:1061–1067
   • MEDLINE
5. Daya S, Gunby J 2004. Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews CD004830.
6. Ditkoff EC, Cassidenti DL, Paulson RJ, et al. The gonadotropin-releasing hormone antagonist (Nal-Glu)acutely blocks the luteinizing hormone surge but allows for resumption offolliculogenesis in normal women. American Journal of Obstetrics and Gynecology. 1991;165:1811–1817
   • Abstract
   • Full-Text PDF (772 KB)
7. Fattinger KE, Verotta D, Porchet HC, et al. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. American Journal of Physiology. 1996;271:E775–E787
8. Felberbaum RE, Reissmann T, Küpker W, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology. 1995;61:151–155
9. Friedler S, Gilboa S, Schachter M, et al. Luteal phase characteristics following GnRH antagonist or agonist treatment – a comparative study. Reproductive BioMedicine Online. 2006;12:27–32
   • Full-Text PDF (108 KB)
   • CrossRef
10. Gordon K, Williams RF, Danforth DR, Hodgen GD. A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. Fertility and Sterility. 1990;54:1140–1145
    • MEDLINE
11. Hugues JN, Cedrin-Durnerin I, Bstandig B et al. 2006 Administration of gonadotropin-releasing hormone agonist during the luteal-phase of GnRH antagonist IVF cycles. Abstracts of the 22nd Annual Meeting of ESHRE, 18–21 June 2006, Prague, Czech Republic, O-007.
12. Kolibianakis EM, Bourgain C, Platteau P, et al. Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility. 2003;80:464–466
    • Full Text
    • Full-Text PDF (54 KB)
    • CrossRef
13. Lambalk CB, Homburg R. GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution. Human Reproduction. 2006;21:2580–2582
14. Macklon NS, Fauser BC. Impact of ovarian hyperstimulation on the luteal phase. Journal of Reproduction and Fertility. 2000;55:101–108
    • MEDLINE
    • CrossRef
15. Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility. 1999;72:1006–1012
    • Abstract
    • Full Text
    • Full-Text PDF (130 KB)
    • CrossRef
16. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Human Reproduction. 2006;21:1894–1900
17. Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Human Reproduction. 2005;20:1798–1804
18. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Human Reproduction. 2002;17:2287–2299
19. Saadat P, Boostanfar R, Slatar C, et al. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertility and Sterility. 2004;82:167–171
    • Abstract
    • Full Text
    • Full-Text PDF (108 KB)
    • CrossRef
20. Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reproductive BioMedicine Online. 2006;13:326–330
    • Abstract
    • Full-Text PDF (208 KB)
    • CrossRef
21. Tesarik J, Hazout A, Mendoza-Tesarik R, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Human Reproduction. 2006;21:2572–2579
22. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Human Reproduction. 2004;19:1176–1180
23. Veeck LL. An Atlas of Human Gametes and Conceptuses: An Illustrated Reference for Assisted Reproductive Technology. New York: Parthenon Publishing; 1999;